Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn
This article was originally published in RPM Report
Executive Summary
The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.
You may also be interested in...
Amgen’s Rebate Bundling Makes It ‘Economically Unfeasible’ For Regeneron To Sell Praluent
Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.
The Slow Death of a Blockbuster
Bad news continues to mount for erythropoiesis-stimulating agents (ESAs), the flagship products of the biotechnology industry. Far from developing new markets, postmarket clinical trials by Amgen and J&J continue to point towards a much smaller appropriate patient population for Aranesp and Procrit.
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.